The mechanism of action of retardation of postmenopausal bone loss may be different for dietary calcium augmentation and hormonal replacement therapy (HRT). We performed a three-arm, placebo-controlled, randomized clinical trial comparing an intake of calcium of 1700 mg with: (1) calcium augmentation with HRT and (2) placebo. One hundred and eighteen women entered the study; 17 patients dropped out of the study. The vast majority of women were less than 2 years postmenopause. Bone mineral density declined significantly in the placebo group. The previously reported rates of change in the HRT group were significantly positive for total body calcium and the trochanter and not significantly different from zero for the others. The rate of change in the calcium augmentation group was intermediate between that in the two other groups, and achieved statistical significance compared with placebo for the total body calcium measurement and for the neck of the femur. Measurements were made prior to treatment and at the end of the study (2.9 years +/- 1.1 SD) for parameters of bone turnover and the calcitrophic hormones, to examine whether the mechanism of action was different for calcium augmentation versus hormonal therapy. There were no changes in the placebo group. The calcium augmentation group had a significant increase in 24-h urinary calcium and declining values for urinary collagen cross-links (pyridinium and deoxypyridinium), urinary hydroxyproline and calcitriol. The group treated with HRT and dietary calcium augmentation also had an increase in urinary calcium and a decline in collagen cross-links and urinary hydroxyproline and skeletal alkaline phosphatase; serum calcitriol did not change. The HRT group also displayed a drop in serum osteocalcin, and an increase in nephrogenous cAMP. Serum parathyroid hormone remained unchanged in all groups. Dietary calcium augmentation retards postmenopausal bone loss by decreasing resorption. The addition of HRT results in a more marked decline in bone resorption parameters and a suppression of parameters of bone formation. Whereas calcium augmentation suppressed calcitriol levels, the addition of HRT resulted in maintenance of calcitriol levels, possibly through enhancement of the renal effects of parathyroid hormone, although other mechanisms are possible.

译文

饮食钙增加和激素替代疗法 (HRT) 的绝经后骨丢失延迟的作用机制可能不同。我们进行了一项三臂,安慰剂对照的随机临床试验,比较了1700 mg钙的摄入量与 :( 1) HRT钙增强和 (2) 安慰剂。一百十八名妇女参加了研究; 17名患者退出了研究。绝大多数女性绝经后不到2年。安慰剂组的骨矿物质密度显着下降。先前报告的HRT组的变化率对全身钙和转子的变化显着阳性,而其他组的变化与零没有显着差异。钙增强组的变化率介于其他两组之间,并且与安慰剂相比,在全身钙测量和股骨颈方面具有统计学意义。在治疗之前和研究结束时 (2.9年/- 1.1 SD) 对骨转换和钙调激素的参数进行了测量,以检查钙增加与激素治疗的作用机制是否不同。安慰剂组没有变化。钙增强组24小时尿钙显着增加,尿胶原交联 (吡啶鎓和脱氧吡啶鎓),尿羟脯氨酸和骨化三醇的值下降。接受HRT和饮食钙增加治疗的组的尿钙也增加,胶原蛋白交联,尿羟脯氨酸和骨骼碱性磷酸酶也减少。血清骨化三醇没有变化。HRT组还显示血清骨钙素下降,肾源性cAMP增加。所有组的血清甲状旁腺激素均保持不变。膳食钙增加通过减少吸收来延缓绝经后骨丢失。添加HRT会导致骨吸收参数明显下降,并抑制骨形成参数。钙的增加抑制了骨化三醇的水平,而HRT的添加可能通过增强甲状旁腺激素的肾脏作用来维持骨化三醇的水平,尽管其他机制也是可能的。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录